This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second opinions: Discussing the standard of care for chronic gout and potential of SEL-212 from Selecta Biosciences
Ticker(s): SELB, HZNWho's the expert?
Institution: University of Miami
- General Rheumatologist physician
- Roughly manages 120-130 patients with Rheumatoid Arthritis
- Has extensive experience in Osteoporosis & Screening and Arthritis & Arthropathy. Has prescribed XELJANZ (tofacitinib) to Rough # of 20-25 patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
